Magnesium supplementation for the management of primary hypertension in adults
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Epidemiological evidence on the effects of magnesium on blood pressure is inconsistent. Metabolic and experimental studies suggest that magnesium may have a role in the regulation of blood pressure. OBJECTIVES: To evaluate the effects of magnesium supplementation as treatment for primary hypertension in adults. SEARCH STRATEGY: We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review. SELECTION CRITERIA: Inclusion criteria were: 1) RCTs of a parallel or crossover design comparing oral magnesium supplementation with placebo, no treatment, or usual care; 2) treatment and follow-up >/=8 weeks; 3) participants over 18 years old, with raised systolic blood pressure (SBP) >/=140 mmHg or diastolic blood pressure (DBP) >/=85 mmHg; 4) SBP and DBP reported at end of follow-up. We excluded trials where: participants were pregnant; received antihypertensive medication which changed during the study; or magnesium supplementation was combined with other interventions. DATA COLLECTION AND ANALYSIS: Two reviewers independently abstracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted. MAIN RESULTS: Twelve RCTs (n=545) with eight to 26 weeks follow-up met our inclusion criteria. The results of the individual trials were heterogeneous. Combining all trials, participants receiving magnesium supplements as compared to control did not significantly reduce SBP (mean difference: -1.3 mmHg, 95% CI: -4.0 to 1.5, I(2)=67%), but did statistically significantly reduce DBP (mean difference: -2.2 mmHg, 95% CI: -3.4 to -0.9, I(2)=47%). Sensitivity analyses excluding poor quality trials yielded similar results. Sub-group analyses and meta-regression indicated that heterogeneity between trials could not be explained by dose of magnesium, baseline blood pressure or the proportion of males among the participants. AUTHORS' CONCLUSIONS: In view of the poor quality of included trials and the heterogeneity between trials, the evidence in favour of a causal association between magnesium supplementation and blood pressure reduction is weak and is probably due to bias. This is because poor quality studies generally tend to over-estimate the effects of treatment. Larger, longer duration and better quality double-blind placebo controlled trials are needed to assess the effect of magnesium supplementation on blood pressure and cardiovascular outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Cited by
Magnesium in man: implications for health and disease
de Baaij, J. H. F., Hoenderop, J. G. J., & Bindels, R. J. M. (2015) · Physiological Reviews · doi:10.1152/physrev.00012.2014 · Cited by 1,726
Magnesium in Prevention and Therapy
Gröber, U., Schmidt, J., & Kisters, K. (2015) · Nutrients · doi:10.3390/nu7095388 · Cited by 1,061
Fiorentini, D., Cappadone, C., Farruggia, G., & Prata, C. (2021) · Nutrients · doi:10.3390/nu13041136 · Cited by 559
Magnesium in Disease Prevention and Overall Health
Volpe, S. L. (2013) · Advances in Nutrition · doi:10.3945/an.112.003483 · Cited by 497
Disorders Involving Calcium, Phosphorus, and Magnesium
Moe, S. M. (2008) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2008.01.007 · Cited by 332
The Importance of Magnesium in Clinical Healthcare
Schwalfenberg, G. K., & Genuis, S. J. (2017) · Scientifica · doi:10.1155/2017/4179326 · Cited by 277
Zhang, X., Li, Y., Del Gobbo, L. C., Rosanoff, A., Wang, J., Zhang, W., & Song, Y. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07664 · Cited by 242
“A significant reduction in diastolic BP but not in systolic BP was consistently identified by a Cochrane review of 12 RCTs among hypertensive patients.(13) In our study, data from 7 trials among 136 treated patients (those taking antihypertensive or diabetic drugs) suggest that both systolic (5.”
ResultEffect of magnesium supplementation on blood pressure: a meta-analysis
Kass, L., Weekes, J., & Carpenter, L. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2012.4 · Cited by 235
“Dickinson et al.(10) reviewed 12 treatment studies of hypertensive patients and reported a small non-significant decrease in SBP of 1.3 mm Hg and a significant reduction of DBP of 2.2 mm Hg. Jee et al.(11) reported a small, non-significant reduction of Received 10 August 2011; revised 12 December 2011; accepted 20 Dec…”
BackgroundInfluentialCostello, R. B., Elin, R. J., Rosanoff, A., Wallace, T. C., Guerrero-Romero, F., Hruby, A., Lutsey, P. L., Nielsen, F. H., Rodriguez-Moran, M., Song, Y., et al. (2016) · Advances in Nutrition · doi:10.3945/an.116.012765 · Cited by 219
“Br J Clin Pharmacol 1999;48(5):655-62.”
Ashworth, A., Mitchell, K., Blackwell, J. R., Vanhatalo, A., & Jones, A. M. (2015) · Public Health Nutrition · doi:10.1017/s1368980015000038 · Cited by 109
Metadata
- Authors
- Dickinson, H. O., Nicolson, D., Campbell, F., Cook, J. V., Beyer, F. R., Ford, G. A., & Mason, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-07-19
- Volume
- 2010
- Issue
- 1
- Pages
- CD004640-CD004640
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1606516178
- Cited by
- 114
- References
- 4
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.